775 results about "Heart disease disorder" patented technology

A plurality of ECG Superscore formulae, created from multiple parameter ECG measurements including those from advanced ECG techniques, can be optimized using additive multivariate statistical models or pattern recognition procedures, with the results compared against a large database of ECG measurements from individuals with known cardiac conditions and/or previous cardiac events. Superscore formulae utilize multiple ECG parameters and accompanying weighting coefficients and allow data obtained from any given patient to be used in calculating that patient's ECG Superscore results. ECG Superscores have retrospectively optimized accuracy for identifying and screening individuals for underlying heart disease and/or for determining the risk of future cardiac events. They thus have greater predictive value than that of any conventional or advanced ECG measurement alone or of any non-optimized combinations of conventional or advanced ECG measurements that have been used in the past. Ongoing optimization of ECG Superscore diagnostic and predictive accuracy may be realized through the iterative adjustment of Superscore formulae based on the incorporation of data from new patients into the database and/or from longitudinal follow-up of the disease and cardiac event status of existing patients.

Methods and apparatus are provided for treating congestive heart failure using a catheter having an inlet end configured for placement in the source of arterial blood such as the aorta, left ventricle or a femoral artery, and an outlet end having at least one conduit configured to be placed in the renal arteries. The catheter includes a lumen through which blood passes from the aorta or left ventricle directly to the renal artery, means for engaging the first conduit with renal artery. The means for engaging also may reduce backflow of blood into the abdominal aorta. The catheter preferably is configured to permit percutaneous, transluminal implantation. Methods of using and implanting the catheter are also provided.

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

The present invention relates to a heart disease automatic classification system based on heart sound analysis. It includes the following several portions: heart sound sensor, it is used for converting heart sound vibration signal of tested person into electric signal and outputting said electric signal; computer with multimedia function, it is connected with heart sound sensor by means of data acquisition card and can be used for recording the heart sound signal of tested person which is outputted by heart sound sensor and storing said signal in storage unit; and heart sound sectionalization program, heart sound characteristics extraction program and classification device which are mounted in the computer. Said invention also provides its working principle and its concrete operation method.

The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2, NF-AT3, calcineurin, MCIP, and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of many of these factors or the pathways mediated by these factors has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides a link between these factors and the pathways they mediate through a family of non-voltage gated channels called TRP channels. The present invention further demonstrates that inhibitors of TRP channels can inhibit or treat heart failure and cardiac hypertrophy.

Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease

The present invention provides novel compounds of Formula I

and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

The present invention relates to the use of erythropoietin for the treatment of disturbances of iron distribution in heart diseases.

Systems and methods assist with managing a chronic disease of a user such as a chronic respiratory or cardiac disease. The system may include a physiological monitor adapted to be carried by the user and operative to sense a physiological parameter of the user. The system may include a management device operatively coupled with the physiological monitor to receive the sensed physiological parameter of the user. The management device, such as with an included processor, may be configured to analyze the physiological and/or environmental parameters to detect a trigger pattern of the parameters, the trigger pattern indicative of a probable event of exacerbation of the chronic respiratory and/or cardiac condition. The management device may then generate automated responses based on the trigger pattern such as by providing instructions for activities and/or treatment for the chronic condition.

The invention relates to the technical field of vegetable-oil soft capsules, in particular to a peony-seed-oil soft capsule and a preparation method thereof. The peony-seed-oil soft capsule is prepared by mixing and gelling of raw materials, capsule pressing and forming, hardening, sizing, scrubbing and drying. The peony-seed-oil soft capsule comprises the following raw materials in parts by weight: 80-95 parts of peony seed oil, 1-3 parts of fucosterol, 1-3 parts of squalene, 1-3 parts of propyl gallate, 0.05-0.25 part of tocopherol, 0.05-0.25 part of soya bean lecithin, 0.15-0.25 part of vitamin C, 5-10 parts of gelatin, 5-10 parts of water, 1.3-2.5 parts of sorbierite, and 2.5-5 parts of glycerol. The peony-seed-oil soft capsule is nutritious and safe, has the obvious effects of reducing blood fat, blood pressure and cholesterol, and can enhance the self immunity, prevent the diabetes, prevent and treat cancers, reduce weight, prevent cerebral stroke and myocardial infarction, clear harmful substances in blood, prevent and treat heart diseases and relieve the climacteric syndrome.

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in the subject. This invention further provides related articles of manufacture and methods.

The invention discloses a Chinese medicinal herb composition for treating hypertensive heart disease and a preparation method thereof, wherein the Chinese medicinal herb composition mainly comprises American ginseng, astragalus mongholicus, stigma croci, poria cocos, radices trichosanthis, semen boitae, dalbergia wood, radix ophiopogonis, radix paeoniae alba, selfheal, natural borneol (d-borneol) and uncaria; the Chinese medicinal herb composition has the effects of benefiting qi and nourishing blood, stopping cardiac pain, regulating qi, eliminating the sense of suppression in the chest and calming the nerves; besides, the Chinese medicinal herb composition has good relief effect on palpitation, choking sensation in chest and stenocardia caused by the hypertensive heart disease, and also has obvious treatment effect on the hypertensive heart disease. As a result, the Chinese medicinal herb composition is an ideal medicine for treating the hypertensive heart disease, and is safe and completely free of side-effect.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).